期刊
ANNUAL REVIEW OF MEDICINE, VOL 67
卷 67, 期 -, 页码 165-183出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-051914-021702
关键词
immunotherapy; adoptive T cell therapy; CD19; CD20; CD30; kappa light chain
资金
- NCI NIH HHS [3P50CA126752, P30 CA125123, P01 CA094237, P50 CA126752] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P50CA126752, P01CA094237, P30CA125123] Funding Source: NIH RePORTER
Lymphomas arise from clonal expansions of B, T, or NK cells at different stages of differentiation. Because they occur in the immunocyte-rich lymphoid tissues, they are easily accessible to antibodies and cell-based immunotherapy. Expressing chimeric antigen receptors (CARs) on T cells is a means of combining the antigen-binding site of a monoclonal antibody with the activating machinery of a T cell, enabling antigen recognition independent of major histocompatibility complex restriction, while retaining the desirable antitumor properties of a T cell. Here, we discuss the basic design of CARs and their potential advantages and disadvantages over other immune therapies for lymphomas. We review current clinical trials in the field and consider strategies to improve the in vivo function and safety of immune cells expressing CARs. The ultimate driver of CAR development and implementation for lymphoma will be the demonstration of their ability to safely and cost-effectively cure these malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据